retatrutide type 2 diabetes phase 2 trial 2024 results Retatrutide, a GIP, GLP-1 and glucagon receptor New Kind of Diabetes Drug

Then, the blots were incubated with the following antibodies overnight at 4 C: mouse anti-GLP-1R (1:200, Santa Cruz, CA, USA), mouse anti-GLP-1 (1:100, Santa Cruz, CA, USA), mouse anti-CGRP (1:100, Santa Cruz, CA, USA), mouse anti-c-fos (1:200, Santa Cruz, CA, USA), rabbit anti-Iba-1 (1:1000, Abcam, Cambridge, MA, USA), rabbit anti-PI3K (1:1000, Proteintech, China), rabbit anti-Akt (1:1000, Proteintech, China), rabbit anti-phospho-Akt (1:2000, Cell Signalling, Boston, MA, USA), rabbit anti-IL-1 (1:800, Wanleibio, China), rabbit anti-TNF- (1:800, Wanleibio, China), and mouse anti--actin (1:1000, Beyotime, China)

Talk to your health care provider as soon as you have concerns about a treatment gap

Without the pharmacological support, the body gravitates back toward its previous setpoint

However, as we embark on a weight management journey, it's crucial to consider the long-term efficacy and sustainability of these treatments